46. Malignant rheumatoid arthritis Clinical trials / Disease details
Clinical trials : 4,356 / Drugs : 2,567 - (DrugBank : 415) / Drug target genes : 192 - Drug target pathways : 228
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04638426 (ClinicalTrials.gov) | September 10, 2020 | 13/11/2020 | Phase 2a Clinical Trial of HL237 for Rheumatoid Arthritis | For 12 Weeks, the Multi Center, Randomized, Double Blinded, Placebo Controlled, Parallel, Dose-finding Clinical Study for the Therapeutic Exploration of Safety and Efficacy Assessment of HL237 Tablet in Patients With Rheumatoid Arthritis (Phase IIa) | Rheumatoid Arthritis | Drug: HL237 tablet;Drug: Placebo of HL237 tablet | Hanlim Pharm. Co., Ltd. | NULL | Enrolling by invitation | 19 Years | N/A | All | 196 | Phase 2 | Korea, Republic of |